Arcus Biosciences, Inc. (RCUS) Stock Price & Analysis
Arcus Biosciences, Inc. (RCUS) rose 1.37% to USD 23.64 as of June 10, 2026 at 03:44 UTC, according to Nexqual real-time market data.
RCUS last closed at USD 23.32; the session ranged USD 22.55–24.32 on volume of 993,237 shares. Market capitalization is $2.97B, with a 52-week range of USD 7.91–28.72 (NYQ). Source: Nexqual, June 10, 2026 at 03:44 UTC.
Key Statistics (as of June 10, 2026 at 03:44 UTC)
| Price | USD 23.64 |
|---|---|
| Change | ▲ 1.37% (up) |
| Previous Close | USD 23.32 |
| Open | USD 23.59 |
| Day Range | USD 22.55 – 24.32 |
| 52-Week Range | USD 7.91 – 28.72 |
| Volume | 993,237 shares |
| Market Cap | $2.97B |
| Exchange | NYQ |
Technical Analysis (RCUS)
Nexqual's technical model rates RCUS "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:44 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.41 (neutral) |
| vs SMA50 | Below (USD 24.04) |
| MACD | -0.11 (negative) |
Analyst Ratings (RCUS)
Wall Street analysts rate RCUS "Strong Buy" based on 12 analysts, with a mean price target of USD 35.75 (range USD 22–47), per Nexqual as of June 10, 2026 at 03:44 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 35.75 |
| High Target | USD 47 |
| Low Target | USD 22 |
| Buy / Hold / Sell | 10 / 3 / 0 |
Earnings (RCUS)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.85 |
| Revenue Estimate | $24.31M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.02 vs est -0.83 ▼ miss |
| 2025-12-31 | USD -0.89 vs est -1.08 ▲ beat |
| 2025-09-30 | USD -1.27 vs est -1.29 ▲ beat |
| 2025-06-30 | USD 0 vs est -1.17 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
Financials & Fundamentals (RCUS)
| Total Revenue | $236.00M |
|---|---|
| Revenue Growth (YoY) | -39.30% |
| Gross Margin | -121.61% |
| Operating Margin | -788.24% |
| Profit Margin | -156.36% |
| ROE | -69.95% |
| Debt / Equity | 21.57 |
| Current Ratio | 4.04 |
| Total Cash | $822.00M |
| Total Debt | $113.00M |
| Free Cash Flow | $-156.00M |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
Financial Health Score (RCUS)
Nexqual rates Arcus Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:44 UTC.
| Growth | Weak — Revenue -4% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $822M cash vs $113M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$156M, burning cash |
| Efficiency | Critical — ROE -70%, ROA -23.1% |
Ownership (RCUS)
| Insider Ownership | +29.13% |
|---|---|
| Institutional Ownership | +72.42% |
| Shares Outstanding | 125.77M |
| Float | 89.11M |
| Short % of Float | +15.32% |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
Leadership (RCUS)
Arcus Biosciences, Inc. is led by Terry J. Rosen (age 65), Co-Founder, Chairman & CEO, per Nexqual as of June 10, 2026 at 03:44 UTC.
| Co-Founder, Chairman & CEO | Terry J. Rosen (age 65) |
|---|---|
| Co- Founder & President | Juan Carlos Jaen (age 67) |
| Principal Financial Officer & CFO | Robert C. Goeltz (age 52) |
| Chief Scientific Officer | Jonathan Yingling (age 56) |
| Vice President of Investor Relations & Strategy | Pia Eaves |
Major Backers & Investors (RCUS)
Notable institutional backers of Arcus Biosciences, Inc. include Gilead Sciences Inc, Wellington Management, Suvretta Capital Management, LLC, according to Nexqual as of June 10, 2026 at 03:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Gilead Sciences Inc | 24.99% |
| Wellington Management | 4.84% |
| Suvretta Capital Management, LLC | 4% |
| Woodline Partners LP | 3% |
| Marshall Wace LLP | 2.99% |
| Siren, L.L.C. | 2.39% |
| Fidelity | 1.27% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 17.79% |
| Vanguard Group | 13.55% |
| State Street | 6.83% |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
From Arcus Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
- The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
- It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer.
- In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SNDX | Syndax Pharmaceuticals, Inc. | USD 17.69 | ▲ 2.02% |
| ARVN | Arvinas, Inc. | USD 7.21 | ▼ 2.83% |
| DNLI | Denali Therapeutics Inc. | USD 20.79 | ▲ 6.51% |
| IDYA | IDEAYA Biosciences, Inc. | USD 28.07 | ▼ 0.78% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:44 UTC. This page is informational and not investment advice.